Cargando…

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan

Vadadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open‐label, 24‐week single‐arm study evaluated the efficacy and safety of vadadustat in 42 Japanese CKD patients with anemia undergoing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nangaku, Masaomi, Kondo, Kazuoki, Takabe, Souichirou, Ueta, Kiichiro, Kaneko, Genki, Otsuka, Makiko, Kawaguchi, Yutaka, Komatsu, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451920/ https://www.ncbi.nlm.nih.gov/pubmed/33283981 http://dx.doi.org/10.1111/1744-9987.13611

Ejemplares similares

A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis
por: Sarnak, Mark J, et al.
Publicado: (2023)

Peritoneal Dialysis-Related Peritonitis Caused by Streptococcus oralis
por: Kotani, Akihiro, et al.
Publicado: (2021)

Increased peritoneal permeability at peritoneal dialysis initiation is a potential cardiovascular risk in patients using biocompatible peritoneal dialysis solution
por: Hamasaki, Yoshifumi, et al.
Publicado: (2014)

Extraperitoneal Placement of a Peritoneal Dialysis Catheter
por: Nakamura, Yasuna, et al.
Publicado: (2018)

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
por: Koury, Mark J., et al.
Publicado: (2022)

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
por: Xiong, Limei, et al.
Publicado: (2022)

Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Time until treatment initiation is associated with catheter survival in peritoneal dialysis-related peritonitis
por: Oki, Rikako, et al.
Publicado: (2021)

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study
por: Harashima, Shin‐ichi, et al.
Publicado: (2018)

Correction to: Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Prognostic significance of concentric left ventricular hypertrophy at peritoneal dialysis initiation
por: Tomura, Misato, et al.
Publicado: (2021)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Hospitalization for Patients on Combination Therapy With Peritoneal Dialysis and Hemodialysis Compared With Hemodialysis
por: Tanaka, Mototsugu, et al.
Publicado: (2020)

Catheter Diversion Procedure With Exit-Site Renewal Promotes Peritoneal Dialysis Catheter Survival
por: Oki, Rikako, et al.
Publicado: (2020)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Haemophilus influenzae peritonitis in a girl on automated peritoneal dialysis: Case report and review of the literature
por: Otsuka, Taketo, et al.
Publicado: (2017)

Hookworm Anemia in a Peritoneal Dialysis Patient in China
por: Wu, Fuquan, et al.
Publicado: (2016)

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Change in Anemia by Carnitine Supplementation in Patients Undergoing Peritoneal Dialysis: A Retrospective Observational Study
por: Kaneko, Shohei, et al.
Publicado: (2021)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
por: Ishii, Taisuke, et al.
Publicado: (2021)

A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity
por: Nakayama, Masaaki, et al.
Publicado: (2020)

Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region
por: Li, Philip Kam Tao, et al.
Publicado: (2021)

Successful Introduction of Peritoneal Dialysis in an End-stage Renal Failure Patient with Idiopathic Aplastic Anemia
por: Suzuki, Yasuhiro, et al.
Publicado: (2020)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Role of anuria in the relationship between indoxyl sulfate and anemia in peritoneal dialysis patients
por: Huang, Jeng-Yi, et al.
Publicado: (2016)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients
por: Ye, Hongjian, et al.
Publicado: (2017)

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO(2)VATE trials
por: Eckardt, Kai-Uwe, et al.
Publicado: (2020)

Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients
por: Hanafusa, Norio, et al.
Publicado: (2014)

Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells
por: Zielniok, Katarzyna, et al.
Publicado: (2020)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Taurolidine Peritoneal Dialysis Catheter Lock to Treat Relapsing Peritoneal Dialysis Peritonitis
por: Alvarez Nadal, Marta, et al.
Publicado: (2020)

Relationship between initial peritoneal dialysis modality and risk of peritonitis
por: Kokubu, Maiko, et al.
Publicado: (2020)

The management of anemia in pediatric peritoneal dialysis patients: Guidelines by an ad hoc European committee
por: Schröder, Cornelis H.
Publicado: (2003)

Peritoneal Dialysis
por: Pyper, R. A.
Publicado: (1948)

Cannot write session to /tmp/vufind_sessions/sess_a0f9208t1epvc4pefdmobgf8u5